Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
2024年9月26日 - 5:05AM
A new partnership between Telesis Bio and Beckman Coulter Life
Sciences, a global leader in laboratory automation and innovation,
will create efficient and scalable biofoundries, delivering
solutions for sustainable and rapid on-premise synthesis of DNA.
This innovative approach enabled by Telesis Bio’s Gibson SOLA
enzymatic reagent platform running on Beckman Coulter Life Sciences
automation to ensures rapid, reliable, and highly scalable
production of extremely high-fidelity DNA, empowering researchers
to achieve greater productivity and innovation in a wide array of
discovery applications.
The collaboration integrates Telesis Bio’s Gibson
SOLA Enzymatic Synthesis technology with the new Biomek Echo One
System from Beckman Coulter Life Sciences. It also delivers an open
solution to the market, allowing the incorporation of constructs
from other providers compatible with Gibson SOLA, further expanding
the technology’s flexibility to synthesize unique or challenging
biology.
“Gibson SOLA Enzymatic DNA Synthesis, in
partnership with Beckman Coulter Life Sciences, is set to
revolutionize synthetic biology through next-generation synthesis
technology. Drawing parallels to the automotive industry’s success
with distributed manufacturing, we aim to establish local and
on-premise DNA foundries that function as digital-to-biologic
converters delivering DNA or mRNA as fast as overnight. By
expanding our network of compatible partners, we continue to drive
forward the capabilities of Gibson SOLA" said Dan Gibson,
Co-Founder and CTO.
Eric Esser, CEO of Telesis Bio, commented on the
collaboration: "This partnership marks a significant milestone in
advancing synthetic biology. By integrating Gibson SOLA's
high-fidelity, scalable, and non-toxic DNA synthesis capabilities
with Beckman Coulter Life Sciences automation expertise, we are
setting a new standard for on-premises biofoundries. This
collaboration empowers researchers to greatly improve productivity
through faster, more reliable, and innovative solutions, driving
forward the next generation of therapeutic and diagnostic
advancements."
“This partnership with Telesis Bio delivers on our
promise to be a trusted and preferred laboratory partner, to more
quickly and accurately enable breakthrough research discoveries,”
said Ewan Grant, Senior Director of the Biotech Workflow Solutions
Business Unit at Beckman Coulter Life Sciences. “This innovation
brings exciting new possibilities to DNA and mRNA synthesis
workflows, unleashing the benefits of our new Biomek Echo One
System including seamlessly executing library preparation steps
such as extraction, fragmentation, ligation, normalization and
pooling along with requisite actions such as centrifugation,
shaking and thermal incubation in one automated method.”
About Telesis Bio Telesis Bio is
empowering scientists to create novel, synthetic biology-enabled
solutions for many of humanity’s greatest challenges. With our
revolutionary Gibson SOLA Enzymatic Synthesis platform, we are
transforming the industry by providing non-toxic, high-fidelity,
and scalable DNA synthesis. The Gibson SOLA platform, combined with
our award-winning BioXp® systems, enables rapid, accurate, and
reproducible writing of DNA and mRNA, automating and optimizing the
entire synthesis, cloning, and amplification workflow. Scientists
worldwide leverage our technology to accelerate the
design-build-test paradigm, driving innovation in precision
medicine, biologics drug discovery, vaccine and therapeutic
development, genome editing, and cell and gene therapy. Telesis Bio
is a public company based in San Diego. For more information, visit
www.telesisbio.com, LinkedIn & About Gibson SOLA.
About Beckman Coulter Life
Sciences With a relentless mission to empower those
seeking answers to life’s important scientific questions, Beckman
Coulter Life Sciences is a preferred laboratory partner providing
automation and innovation solutions for Centrifugation, Flow
Cytometry, Genomics, Particle Analysis, and Liquid Handling
workflows. With a legacy dating back to 1935, our technologies
reduce manual laboratory processes and can provide greater speed,
accuracy, and advanced analytics to accelerate answers with a
guiding focus to improve patient care and enable pioneering
discoveries. Beckman Coulter Life Sciences is headquartered in
Indianapolis, Indiana with 11 operational hubs around the world and
employs approximately 2,800 associates with more than 400,000
systems installed globally. Get to know us by clicking
here and by following us on LinkedIn.
Contact: Matt McCutcheon, Global
External Communications Manager, mmccutcheon@beckman.com,
317-719-0557
Telesis Bio (NASDAQ:TBIO)
過去 株価チャート
から 10 2024 まで 11 2024
Telesis Bio (NASDAQ:TBIO)
過去 株価チャート
から 11 2023 まで 11 2024